119 related articles for article (PubMed ID: 10775267)
21. Infantile fibrosarcoma misdiagnosed as vascular tumors.
Hayek SN; Janom HH; Ibrahim A; Moran SL
Hand (N Y); 2013 Dec; 8(4):464-8. PubMed ID: 24426968
[TBL] [Abstract][Full Text] [Related]
22. TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1.
Kim MS; Kim GM; Choi YJ; Kim HJ; Kim YJ; Jin W
Mol Cells; 2013 Aug; 36(2):177-84. PubMed ID: 23832765
[TBL] [Abstract][Full Text] [Related]
23. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.
Iyer R; Varela CR; Minturn JE; Ho R; Simpson AM; Light JE; Evans AE; Zhao H; Thress K; Brown JL; Brodeur GM
Cancer Chemother Pharmacol; 2012 Sep; 70(3):477-86. PubMed ID: 22623209
[TBL] [Abstract][Full Text] [Related]
24. Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases.
Wang J; Hancock MK; Dudek JM; Bi K
Curr Chem Genomics; 2008 Feb; 1():27-33. PubMed ID: 20161825
[TBL] [Abstract][Full Text] [Related]
25. Dissecting the dynamics of dysregulation of cellular processes in mouse mammary gland tumor.
Mentzen WI; Floris M; de la Fuente A
BMC Genomics; 2009 Dec; 10():601. PubMed ID: 20003387
[TBL] [Abstract][Full Text] [Related]
26. Trk receptor expression and inhibition in neuroblastomas.
Brodeur GM; Minturn JE; Ho R; Simpson AM; Iyer R; Varela CR; Light JE; Kolla V; Evans AE
Clin Cancer Res; 2009 May; 15(10):3244-50. PubMed ID: 19417027
[TBL] [Abstract][Full Text] [Related]
27. High-affinity neurotrophin receptors and ligands promote leukemogenesis.
Li Z; Beutel G; Rhein M; Meyer J; Koenecke C; Neumann T; Yang M; Krauter J; von Neuhoff N; Heuser M; Diedrich H; Göhring G; Wilkens L; Schlegelberger B; Ganser A; Baum C
Blood; 2009 Feb; 113(9):2028-37. PubMed ID: 19059881
[TBL] [Abstract][Full Text] [Related]
28. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Tam WF; Gu TL; Chen J; Lee BH; Bullinger L; Fröhling S; Wang A; Monti S; Golub TR; Gilliland DG
Blood; 2008 Sep; 112(5):1981-92. PubMed ID: 18559972
[TBL] [Abstract][Full Text] [Related]
29. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.
Barry EV; Clark JJ; Cools J; Roesel J; Gilliland DG
Blood; 2007 Dec; 110(13):4476-9. PubMed ID: 17827387
[TBL] [Abstract][Full Text] [Related]
30. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Dong S; Kang S; Gu TL; Kardar S; Fu H; Lonial S; Khoury HJ; Khuri F; Chen J
Blood; 2007 Jul; 110(1):360-9. PubMed ID: 17389761
[TBL] [Abstract][Full Text] [Related]
31. Ott1(Rbm15) has pleiotropic roles in hematopoietic development.
Raffel GD; Mercher T; Shigematsu H; Williams IR; Cullen DE; Akashi K; Bernard OA; Gilliland DG
Proc Natl Acad Sci U S A; 2007 Apr; 104(14):6001-6. PubMed ID: 17376872
[TBL] [Abstract][Full Text] [Related]
32. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis.
Scholl C; Bansal D; Döhner K; Eiwen K; Huntly BJ; Lee BH; Rücker FG; Schlenk RF; Bullinger L; Döhner H; Gilliland DG; Fröhling S
J Clin Invest; 2007 Apr; 117(4):1037-48. PubMed ID: 17347684
[TBL] [Abstract][Full Text] [Related]
33. The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor.
Jin W; Kim BC; Tognon C; Lee HJ; Patel S; Lannon CL; Maris JM; Triche TJ; Sorensen PH; Kim SJ
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16239-44. PubMed ID: 16258068
[TBL] [Abstract][Full Text] [Related]
34. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
[TBL] [Abstract][Full Text] [Related]
35. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype.
Growney JD; Shigematsu H; Li Z; Lee BH; Adelsperger J; Rowan R; Curley DP; Kutok JL; Akashi K; Williams IR; Speck NA; Gilliland DG
Blood; 2005 Jul; 106(2):494-504. PubMed ID: 15784726
[TBL] [Abstract][Full Text] [Related]
36. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion.
Mulloy JC; Jankovic V; Wunderlich M; Delwel R; Cammenga J; Krejci O; Zhao H; Valk PJ; Lowenberg B; Nimer SD
Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4016-21. PubMed ID: 15731354
[TBL] [Abstract][Full Text] [Related]
37. Directing oncogenic fusion genes into stem cells via an SCL enhancer.
Eguchi M; Eguchi-Ishimae M; Green A; Enver T; Greaves M
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1133-8. PubMed ID: 15650051
[TBL] [Abstract][Full Text] [Related]
38. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Chen J; Deangelo DJ; Kutok JL; Williams IR; Lee BH; Wadleigh M; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Galinsky I; Huntly B; Cohen PS; Meyer T; Fabbro D; Roesel J; Banerji L; Griffin JD; Xiao S; Fletcher JA; Stone RM; Gilliland DG
Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14479-84. PubMed ID: 15448205
[TBL] [Abstract][Full Text] [Related]
39. The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.
Okuda K; Sato Y; Sonoda Y; Griffin JD
Int J Hematol; 2004 Feb; 79(2):138-46. PubMed ID: 15005341
[TBL] [Abstract][Full Text] [Related]
40. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.
Chan IT; Kutok JL; Williams IR; Cohen S; Kelly L; Shigematsu H; Johnson L; Akashi K; Tuveson DA; Jacks T; Gilliland DG
J Clin Invest; 2004 Feb; 113(4):528-38. PubMed ID: 14966562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
